FutureChem Signs $1.25 Million Contract for Clinical Trial Radiopharmaceuticals Manufacturing and Supply

[Asia Economy Reporter Lee Gwan-joo] FutureChem, a company specializing in radiopharmaceuticals, announced on the 18th that it has signed a contract with AVID, a subsidiary of Eli Lilly, for the contract manufacturing and supply of radiopharmaceuticals for clinical trials.

The contract is valued at $1,259,000 (approximately 1.54 billion KRW) and involves the contract manufacturing and supply of radiopharmaceuticals for Alzheimer's diagnosis required for domestic clinical trials.

AVID is a U.S.-based radiopharmaceutical company and a subsidiary of the global pharmaceutical company Eli Lilly. Eli Lilly acquired AVID in 2010 for $800 million to develop dementia treatments.

A FutureChem official stated, "This contract is significant as it is the first contract manufacturing and supply agreement for radiopharmaceuticals for clinical trials with a global pharmaceutical company," adding, "We will expand new business supplying radiopharmaceuticals for clinical trials to global pharmaceutical companies conducting clinical trials in Korea."

This content was produced with the assistance of AI translation services.